The FDA has recently approved several groundbreaking treatments for gastroenterology, including the first blood test for colorectal cancer. Despite a summer lull, three approvals for GI have closed out the season. Some notable approvals include Skyrizi for ulcerative colitis and Crohn’s disease, a rapid test for hepatitis C virus, and Livdelzi for primary biliary cholangitis. Other approvals include biosimilars, breakthrough therapies, and expanded indications for existing drugs. These approvals are expected to change the treatment paradigm for gastroenterology and hepatology in 2024 and beyond.
Source link
Health Information Management